38647-81-3

Basic information

• Product Name: (3-Chlorophenyl)guanidine (Mononitrate)
• Synonyms: (3-Chlorophenyl)guanidine (Mononitrate)
• CAS NO: 38647-81-3
• Molecular Formula: C₇H₈ClN₃*HNO₃
• Molecular Weight: 232.62436
• Mol File: 38647-81-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3-Chlorophenyl)guanidine (Mononitrate)(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Chlorophenyl)guanidine (Mononitrate)(38647-81-3)
• EPA Substance Registry System: (3-Chlorophenyl)guanidine (Mononitrate)(38647-81-3)

Safety Data

• Hazardous Substances Data: 38647-81-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Healthcare Industry:
(3-Chlorophenyl)guanidine (Mononitrate) is used as an antiseptic and disinfectant for its effectiveness against a broad spectrum of bacteria and fungi. It plays a crucial role in maintaining hygiene and preventing infections in various healthcare settings.
Used in Topical Antimicrobial Agents:
As a component of topical antimicrobial agents, (3-Chlorophenyl)guanidine (Mononitrate) helps in treating skin infections and promoting faster healing by eliminating harmful microorganisms.
Used in Oral Care Products:
(3-Chlorophenyl)guanidine (Mononitrate) is used as an active ingredient in mouthwashes and toothpastes, contributing to oral hygiene by combating bacteria and fungi that cause dental issues such as gingivitis and plaque buildup.

Upstream product

• 420-04-2 CYANAMID 
• 108-42-9 3-chloro-aniline 

Downstream Products

• 862460-71-7 2-(3-chloro-phenylamino)-4-isopropyl-pyrimidine-5-carboxylic acid ethyl ester 
• 862460-76-2 ethyl 2-[(3-chlorophenyl)amino]-4-[1-(dimethylamino)ethyl]-5-pyrimidinecarboxylate 
• 652153-37-2 (3-chlorophenyl)-[4-(2-chloropyridin-4-yl)-[1,3,5]triazin-2-yl]amine 
• 863774-12-3 2-(3-chloro-phenylamino)-4-cyclopropyl-pyrimidine-5-carboxylic acid methyl ester 
• 1082014-00-3 C₁₉H₁₈ClN₅O₂ 
• 1383718-45-3 N-(3-chlorophenyl)-5,6,7,8-tetrahydroquinazolin-2-amine 
• 881677-74-3 (3-chloro-phenyl)-[4-(6-chloro-pyridin-3-yl)-pyrimidin-2-yl]-amine 
• 1082013-94-2 propan-2-yl 3-{2-[(3-chlorophenyl)amino]pyrimidin-4-yl}pyridine-2-carboxylate 
• 1082013-95-3 2-methoxyethyl 3-{2-[(3-chlorophenyl)amino]pyrimidin-4-yl}pyridine-2-carboxylate 
• 164658-40-6 (3-chloro-phenyl)-[4-(2-chloro-pyridin-4-yl)-pyrimidin-2-yl]-amine 
• 1383718-48-6 2-((3-chlorophenyl)amino)-7,8-dihydroquinazolin-5(6H)-one 
• 1383718-55-5 (rac)-2-((3-chlorophenyl)amino)-7-methyl-7,8-dihydroquinazolin-5(6H)-one 

Relevant articles and documents

2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity

Following the identification through virtual screening of 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analogue program was initiated. The first aims were to optimize potency and to evaluate the cellular mode of action of lead candidate molecules. Here the synthetic chemistry, the structure-guided design approach, and the structure-activity relationships (SARs) that led to the discovery of 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors, many with very low nM Kis against CDK2, are reported. Furthermore, X-ray crystal structures of four representative analogues from our chemical series in complex with CDK2 are presented, and these structures are used to rationalize the observed biochemical SARs. Finally results are reported that show, using the most potent CDK2 inhibitor compound from the current series, that the observed antiproliferative and proapoptotic effects are consistent with cellular CDK2 and CDK9 inhibition.

Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof

Described are N-phenyl-2-pyrimidineamine derivatives of formula I STR1 wherein R1 is a substituted cyclic radical, the cyclic radical being bonded at a ring carbon atom in each case and being selected from phenyl, pyridyl, pyrazinyl, thiazolyl, pyrimidinyl, pyridazinyl and imidazolyl, and the substituents of the above-mentioned cyclic radical being selected from one or more of the groups halogen, cyano, carbamoyl, --C(=O)--OR3, --C(=O)--R4, --SO2 --N(R5)--R6, --N(R7)--R8, --OR9 and fluorine-substituted lower alkyl, wherein R3, R4, R5, R6, R7, R8 and R9 are each independently of the others hydrogen or lower alkyl that is unsubstituted or substituted by mono- or di-lower alkylamino; and R2 is selected from halogen, cyano, carbamoyl, --C(=O)--OR10, --C(=O)--R11, --SO2 --N(R12)--R13, --N(R14)--R15, --OR16 and fluorine-substituted lower alkyl, wherein R10, R11, R12, R13, R14, R15 and R16 are each independently of the others hydrogen or lower alkyl that is unsubstituted or substituted by mono- or di-lower alkylamino. Those compounds can be used, for example, in the treatment of tumour diseases.